Sanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue Estimates

Company Performance - Sanara MedTech Inc. reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.33, and an improvement from a loss of $0.41 per share a year ago, representing an earnings surprise of +30.30% [1] - The company posted revenues of $25.83 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.70%, and showing an increase from $20.16 million in the same quarter last year [2] - Over the last four quarters, Sanara MedTech has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Sanara MedTech shares have declined approximately 17.3% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] - The current Zacks Rank for Sanara MedTech is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.32 on revenues of $26.65 million, and for the current fiscal year, it is -$1.56 on revenues of $106.93 million [7] - The trend of estimate revisions for Sanara MedTech was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which Sanara MedTech belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]